Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Topic
Drug Pricing
WAC, ASP, NADAC, IRA negotiated prices, inflation rebates, and drug cost trends affecting access and coverage.
Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Policy· June 30, 2026 · 18 min read
FDA Market Exclusivity by the Numbers: Exclusivity and GAIN Registry Analysis
By Ran Chen#Orange Book#Generics#Generic Entry
Generics· June 29, 2026 · 18 min read
Generic Xarelto Entry: Orange Book Patents and NADAC Price Erosion
By Ran Chen#Generics#Orange Book#Generic Entry
Policy· June 28, 2026 · 17 min read
Medicaid Drug Rebate Program Explained: AMP, Best Price, and the CPI Penalty
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Generics· June 26, 2026 · 22 min read
Generic Revlimid REMS Launch: Lenalidomide ANDA Entry and NADAC Absence
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 26, 2026 · 21 min read
Generic Tecfidera: Dimethyl Fumarate Patent Settlements and NADAC Erosion
By Ran Chen#Generics#Orange Book#PBM
Generics· June 26, 2026 · 21 min read
Generic Zytiga: Abiraterone Acetate ANDA Saturation and NADAC Pricing
By Ran Chen#Generics#Orange Book#Oncology
Generics· June 25, 2026 · 19 min read
Generic Copaxone: FDA Guidance and NADAC Pricing Dynamics
By Ran Chen#Generics#Orange Book#FDA Approval
Generics· June 25, 2026 · 19 min read
Generic Gilenya: Dosing Patent Expiry and 99% Price Erosion
By Ran Chen#Generics#Orange Book#PBM